At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KROS Keros Therapeutics, Inc.
Pre-Market Trading 12-23 08:45:27 EST
17.03
+0.11
+0.65%
盘前17.13
+0.10+0.61%
08:42 EST
High17.64
Low16.62
Vol1.47M
Open16.77
D1 Closing16.92
Amplitude6.02%
Mkt Cap689.84M
Tradable Cap602.37M
Total Shares40.51M
T/O25.07M
T/O Rate4.15%
Tradable Shares35.37M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.